Selank/Semax – Nasal Spray

Selank/Semax Nasal Spray is a custom-compounded intranasal solution containing Selank 2 mg/mL and Semax 2 mg/mL (2 mg/2 mg per mL), available in pharmacy-dispensed spray bottles or as This dual-peptide formulation leverages Selank’s unique anxiolytic and neuroimmune modulating activities (a tuftsin analog) with Semax’s neurotrophic and cognitive-enhancing effects (an ACTH4–10 fragment). Both are designed for non-invasive, rapid delivery to the central nervous system, for investigational protocols targeting mood, stress, cognition, and post-stroke neuroprotection.

Selank modulates GABAergic neurotransmission as a positive allosteric modulator of GABA-A receptors, shifting neurotransmission and gene expression involved in stress, cognitive, and immune systems. Semax upregulates neuroplasticity and neurotransmitter pathway genes, increases BDNF, provides neuroprotection, and enhances networks related to learning and executive function, supporting both recovery and cognitive enhancement.

Synergistic Cognitive Effects: The combination provides both anxiolytic (Selank) and cognitive enhancement (Semax) properties. Selank contributes to learning and memory benefits through BDNF modulation, while Semax provides neuroprotection via ACTH-like effects.

Synergistic Cognitive Effects: The combination provides both anxiolytic (Selank) and cognitive enhancement (Semax) properties. Selank contributes to learning and memory benefits through BDNF modulation, while Semax provides neuroprotection via ACTH-like effects.

Both peptides are typically well tolerated. Adverse effects are mild and transient: nasal dryness, irritation, burning, headache, or dizziness. No sedation, withdrawal, dependence, or serious toxicity is documented; rare allergic events should prompt discontinuation.

Contraindicated in those with peptide or excipient hypersensitivity. Do not use it in pregnancy, lactation, childhood, or with untreated severe psychiatric illness absent specialist supervision. Monitor when used with other CNS-active medications. No hepatic/renal adjustment data exists; use caution in these populations.

After clearing nasal passages, spray 1–2 sprays per nostril (each delivering approximately 0.1–0.12 mL, equal to 0.2–0.24 mg of each peptide), one or two times daily as directed. Start at the lowest effective dose and titrate per tolerability and clinical response. Typical cycles last 10–30 days, with breaks between courses. Warm spray bottle briefly in hand before use, then return to refrigeration. For compounded